Dafna Bar-Sagi

Last updated
Dafna Bar-Sagi
Born
Israel
Alma mater State University of New York at Stony Brook, Bar-Ilan University
Scientific career
Institutions New York University School of Medicine, NYU Langone Health.
Academic advisorsJames Feramisco [1]

Dafna Bar-Sagi is a cell biologist and cancer researcher at New York University School of Medicine. [1] She is the Saul J. Farber Professor in the department of biochemistry and molecular pharmacology and the department of medicine and senior vice president and vice dean for science at NYU Langone Health. [2] Bar-Sagi has been a member of scientific advisory boards, including the National Cancer Institute, [3] Starr Cancer Consortium, [4] and Pancreatic Cancer Action Network. [5]

Contents

Her research focuses on the nature of the Ras oncogene and how Ras signaling leads to tumor development, particularly in pancreatic cancer. [6] [7]

Early life

Education

Dafna Bar-Sagi was born and raised in Israel. [1] She attended Bar-Ilan University where she earned her undergraduate and master's degrees in neurobiology. She received her PhD in neurobiology in the United States from the State University of New York at Stony Brook (SUNY). [8] [1]

Career

Dafna Bar-Sagi conducted her postdoctoral research in the lab of James Feramisco in Cold Spring Harbor Laboratory, where she worked on the nature of the Ras proteins in 1986, and eventually served as senior staff investigator. [9]

In 1995, Bar-Sagi became faculty at the department of molecular genetics and microbiology at State University of New York (SUNY) at Stony Brook and served as the department chair from 2003 to 2006. [10]

Bar-Sagi transitioned to NYU Langone Medical Center in 2006 as chair of the department of biochemistry. [6] She became vice dean for science and chief scientific officer at NYU Langone Health in 2011. She became executive vice president in 2019. [11]

Research

Dafna Bar-Sagi's research began in 1986, while completing her postdoctoral work with Dr. James Feramisco in Cold Spring Harbor. [1] [12] Bar-Sagi and Feramisco were the first to observe how Ras protein facilitates cellular uptake of nutrients through macropinocytosis. [13] [14] [1]

Bar-Sagi continues to study the function of Ras oncogenes and mutant Ras proteins [15] in cell proliferation, survival, nutrient uptake, cell metabolism and tumorigenesis, [15] particularly in pancreatic cancer. [7] Recent studies in the Bar-Sagi lab have focused on the treatment of mutant KRAS cancer cells, and understanding how they withstand targeted therapies, as well as identification of novel therapeutic strategies for Ras-driven cancers. [16] Her research on interleukin-1β suggests that to fully understand the interactions between tumors, their environment, and immune system, researchers will have to find new methods of studying tumors in vivo . [9]

Selected publications

Recent Publications
YearCitation
2018Cullis, Jane; Das, Shipra; Bar-Sagi, Dafna. Kras and Tumor Immunity: Friend or Foe? Cold Spring Harbor Perspectives In Medicine. 2018 Sep 04; 8(9): [2]
2018Handler, Jesse; Cullis, Jane; Avanzi, Antonina; Vucic, Emily A; Bar-Sagi, Dafna. Pre-Neoplastic Pancreas Cells Enter a Partially Mesenchymal State Following Transient TGF-î² Exposure. Oncogene. 2018 Aug 02; 37(31):4334-4342 [2]
2018Aiello, Nicole M; Maddipati, Ravikanth; Norgard, Robert J; Balli, David; Li, Jinyang; Yuan, Salina; Yamazoe, Taiji; Black, Taylor; Sahmoud, Amine; Furth, Emma E; Bar-Sagi, Dafna; Stanger, Ben Z. EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration. Developmental Cell. 2018 Jun 18; 45(6):681-695.e4 [2]
2017Jang, Jung-Eun; Hajdu, Cristina H; Liot, Caroline; Miller, George; Dustin, Michael L; Bar-Sagi, Dafna. Crosstalk Between Regulatory T Cells and Tumor-Associated Dentritic Cells Negates Anti-Tumor Immunity in Pancreatic Cancer. Cell Reports. 2017 Jul 18; 20(3):558-571 [2]
2017Cohen, D J; Grabocka, E; Bar-Sagi, D; Godin, R; Leichman, L P. A Phase lb Studying Combining Irinotecan With AZD1775, A Selective WEE 1 Kinase Inhibitor, in RAS/RAF Mutated Metastatic Colorectal Cancer Patients Who Progressed on First Line Therapy [Meeting Abstract]. Journal Of Clinical Oncology. 2017 Jun 20; (2017): [2]
2017Fehrenbacher, Nicole; Tojal da Silva, Israel; Ramirez, Craig; Zhou, Yong; Cho, Kwang-Jin; Kuchay, Shafi; Shi, Jie; Thomas, Susan; Pagano, Michele; Hancock, John F; Bar-Sagi, Dafna; Philips, Mark R. The G Proteined-Coupled Receptors GPR31 Promotes Membrane Association of KRAS. Journal Of Cell Biology. 2017 Jun 15; 216(8):2329-2338 [2]
2017Cullis, Jane E; Siolas, Despina; Avanzi, Antonina; Barui, Sugata; Maitra, Anirban; Bar-Sagi, Dafna. Macropinocytosis of Nab-Paclitaxel Drives Macrophage Activation in Pancreatic Cancer. Cancer Immunology Research. 2017 Jan 20; 5(3):182-190 [2]
2017Grabocka, Elda; Bar-Sagi, Dafna. Stress Granules in Pancreatic Cancer: Drug & Resistance Treatment. Oncology Times. 2017; 39(4):30-34 [2]
2013Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S, Grabocka E, Nofal M, Drebin JA, Thompson CB, Rabinowitz JD, Metallo CM, Vander Heiden MG, Bar-Sagi D. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature. 2013 May 30;497(7451):633-7. [2]
2012Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell. 2012 Jun 12;21(6): 836–47.

Awards and honors

Membership on Scientific Advisory Boards and Boards of Directors

Related Research Articles

<span class="mw-page-title-main">Ras GTPase</span> GTP-binding proteins functioning on cell-cycle regulation

Ras, from "Rat sarcoma virus", is a family of related proteins that are expressed in all animal cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in three-dimensional structure and regulate diverse cell behaviours.

<span class="mw-page-title-main">Bert Vogelstein</span> American oncologist (born 1949)

Bert Vogelstein is director of the Ludwig Center, Clayton Professor of Oncology and Pathology and a Howard Hughes Medical Institute investigator at The Johns Hopkins Medical School and Sidney Kimmel Comprehensive Cancer Center. A pioneer in the field of cancer genomics, his studies on colorectal cancers revealed that they result from the sequential accumulation of mutations in oncogenes and tumor suppressor genes. These studies now form the paradigm for modern cancer research and provided the basis for the notion of the somatic evolution of cancer.

<span class="mw-page-title-main">Guanine nucleotide exchange factor</span> Proteins which remove GDP from GTPases

Guanine nucleotide exchange factors (GEFs) are proteins or protein domains that activate monomeric GTPases by stimulating the release of guanosine diphosphate (GDP) to allow binding of guanosine triphosphate (GTP). A variety of unrelated structural domains have been shown to exhibit guanine nucleotide exchange activity. Some GEFs can activate multiple GTPases while others are specific to a single GTPase.

<span class="mw-page-title-main">KRAS</span> Protein-coding gene in humans

KRAS is a gene that provides instructions for making a protein called K-Ras, a part of the RAS/MAPK pathway. The protein relays signals from outside the cell to the cell's nucleus. These signals instruct the cell to grow and divide (proliferate) or to mature and take on specialized functions (differentiate). It is called KRAS because it was first identified as a viral oncogene in the KirstenRAt Sarcoma virus. The oncogene identified was derived from a cellular genome, so KRAS, when found in a cellular genome, is called a proto-oncogene.

<span class="mw-page-title-main">NYU Langone Health</span> Hospital in New York, United States

NYU Langone Health is an academic medical center located in New York City, New York, United States. The health system consists of NYU Grossman School of Medicine and NYU Long Island School of Medicine, both part of New York University (NYU), and more than 300 locations throughout the New York metropolitan area, including six inpatient facilities: Tisch Hospital, Kimmel Pavilion, NYU Langone Orthopedic Hospital, Hassenfeld Children's Hospital, NYU Langone Hospital – Brooklyn and NYU Langone Hospital – Long Island. It is also home to Rusk Rehabilitation. NYU Langone Health is one of the largest healthcare systems in the Northeast, with more than 46,000 employees.

Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses.

<span class="mw-page-title-main">Joan Massagué</span> Spanish biologist

Joan Massagué, is a Spanish biologist and the current director of the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center. He is also an internationally recognized leader in the study of both cancer metastasis and growth factors that regulate cell behavior, as well as a professor at the Weill Cornell Graduate School of Medical Sciences.

<span class="mw-page-title-main">Aviv Regev</span> Bioinformatician

Aviv Regev is a computational biologist and systems biologist and Executive Vice President and Head of Genentech Research and Early Development in Genentech/Roche. She is a core member at the Broad Institute of MIT and Harvard and professor at the Department of Biology of the Massachusetts Institute of Technology. Regev is a pioneer of single cell genomics and of computational and systems biology of gene regulatory circuits. She founded and leads the Human Cell Atlas project, together with Sarah Teichmann.

The Pancreatic Cancer Action Network (PanCAN) is a United States-based 501(c)(3) charity that funds research, provides patient/caregiver support, conducts community outreach and advocates for increased federal research funding for those affected by pancreatic cancer.

<span class="mw-page-title-main">Dana Pe'er</span> Bioinformatician

Dana Pe'er, Chair and Professor in Computational and Systems Biology Program at Sloan Kettering Institute is a researcher in computational systems biology. A Howard Hughes Medical Institute (HHMI) Investigator since 2021, she was previously a professor at Columbia Department of Biological Sciences. Pe'er's research focuses on understanding the organization, function and evolution of molecular networks, particularly how genetic variations alter the regulatory network and how these genetic variations can cause cancer.

<span class="mw-page-title-main">William Kaelin Jr.</span> American Nobel Laureate, Professor of Medicine at Harvard University

William G. Kaelin Jr. is an American Nobel laureate physician-scientist. He is a professor of medicine at Harvard University and the Dana–Farber Cancer Institute. His laboratory studies tumor suppressor proteins. In 2016, Kaelin received the Albert Lasker Award for Basic Medical Research and the AACR Princess Takamatsu Award. He also won the Nobel Prize in Physiology or Medicine in 2019 along with Peter J. Ratcliffe and Gregg L. Semenza.

Professor Carol L. Prives FRS is the Da Costa Professor of Biological Sciences at Columbia University. She is known for her work in the characterisation of p53, an important tumor suppressor protein frequently mutated in cancer.

Kevan Michael Shokat is an American chemical biologist. He is a Professor and chair in the Department of Cellular and Molecular Pharmacology at University of California, San Francisco, a professor in the Department of Chemistry at University of California, Berkeley, and an Investigator with the Howard Hughes Medical Institute.

<span class="mw-page-title-main">Elizabeth Jaffee</span> American oncologist

Elizabeth M. Jaffee is an American oncologist specializing in pancreatic cancer and immunotherapy.

Cosimo Commisso is a Canadian cell biologist and cancer researcher who has made significant advances in the field of cellular trafficking and cancer metabolism. Among his most notable contributions are the discovery and study of how macropinocytosis supports tumor cell growth and survival by serving as an amino acid supply route in Ras-mutated cancers. He is currently an associate professor in the Tumor Initiation and Maintenance Program at the Sanford Burnham Prebys Medical Discovery Institute NCI-designated Cancer Center in La Jolla, California, USA.

Guillermina 'Gigi' Lozano is an American geneticist. She is a professor at University of Texas MD Anderson Cancer Center. Lozano is recognised for her studies of the p53 tumour suppressor pathway, characterising the protein as a regulator of gene expression.

Antoni Ribas is a Spanish-American physician‐scientist. He is a Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA) and Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center. Ribas served as president of the American Association for Cancer Research (AACR) in 2021-2022.

Channing Joseph Der is an American scientist and educator, and Sarah Graham Kenan Distinguished Professor of Pharmacology, at UNC Lineberger Comprehensive Cancer Center. Der is a Fellow of the American Association for the Advancement of Science, He is recognized for his work with the Ras oncoprotein and its role in human oncogenesis.

Lisa M. Coussens is an American cancer scientist who is Chair of the Department of Cell, Developmental and Cancer Biology and Professor and Associate Director for Basic Research in the Knight Cancer Institute at the Oregon Health & Science University. She serves as President of the American Association for Cancer Research.

<span class="mw-page-title-main">Edna Cukierman</span> Mexican biochemist and academic

Edna "Eti" Cukierman is a Mexican biochemist who is a professor at the Fox Chase Cancer Center. She serves as co-director of the Marvin & Concetta Greenberg Pancreatic Cancer Institute. Her research investigates pancreatic cancer and the tumor microenvironment.

References

  1. 1 2 3 4 5 6 "A Conversation with Dafna Bar-Sagi". National Cancer Institute. 2016-03-30. Retrieved 2018-10-06.
  2. 1 2 3 4 5 6 7 8 9 10 "Dafna Bar-Sagi". med.nyu.edu. Retrieved 2018-10-07.
  3. 1 2 "National Institutes of Health, National Cancer Institute, Board of Scientific Advisors" (PDF). Retrieved 2022-04-28.
  4. 1 2 "Scientific Review Board". www.starrcancer.org. Retrieved 2020-05-02.
  5. 1 2 "Scientific and Medical Advisory Board - Pancreatic Cancer Action Network". Pancreatic Cancer Action Network. Retrieved 2020-05-02.
  6. 1 2 "Dafna Bar-Sagi". National Academy of Sciences. Retrieved 28 April 2022.
  7. 1 2 "Dafna Bar-Sagi, PhD". American Association for Cancer Research (AACR). Retrieved 28 April 2022.
  8. ↑ "Three NYU Faculty Elected to National Academy of Sciences". New York University. May 4, 2020. Retrieved 28 April 2022.
  9. 1 2 Mast, Jason (9 January 2020). "How pancreatic RAS tumors protect themselves. Researchers point to a new protein — and maybe a new treatment". Pershing Square Foundation. Retrieved 28 April 2022.
  10. ↑ "Dafna Bar-Sagi, PhD". Pancreatic Cancer Action Network. Retrieved 28 April 2022.
  11. ↑ "Dafna Bar-Sagi, PhD". New York Genome Center. Retrieved 28 April 2022.
  12. ↑ Bar-Sagi, D.; Feramisco, J. R. (5 September 1986). "Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins". Science. 233 (4768): 1061–1068. Bibcode:1986Sci...233.1061B. doi:10.1126/science.3090687. ISSN   0036-8075. PMID   3090687 . Retrieved 28 April 2022.
  13. ↑ "the definition of pinocytosis". www.dictionary.com. Retrieved 2018-10-07.
  14. ↑ Recouvreux, Maria Victoria; Commisso, Cosimo (29 September 2017). "Macropinocytosis: A Metabolic Adaptation to Nutrient Stress in Cancer". Frontiers in Endocrinology. 8: 261. doi: 10.3389/fendo.2017.00261 . ISSN   1664-2392. PMC   5649207 . PMID   29085336.
  15. 1 2 3 4 "2014 Grant Recipient Daphna Bar-Sagi, PhD – Pancreatic Cancer Action Network/". Pancreatic Cancer Action Network. Retrieved 2018-10-06.
  16. ↑ Brooks, Megan (December 15, 2016). "Coping mechanism suggests new way to make cancer cells more vulnerable to chemotherapies". ScienceDaily / Reuters Health. Retrieved 28 April 2022.
  17. ↑ "National Academy of Sciences Elects New Members". National Academy of Sciences. April 27, 2020. Retrieved 2020-05-02.
  18. ↑ "Fellows of the AACR Academy: Class Year 2019". American Association for Cancer Research (AACR). Retrieved 2020-05-02.
  19. ↑ "AACR-Women in Cancer Research Charlotte Friend Lectureship: Past Recipients". American Association for Cancer Research (AACR). Retrieved 28 April 2022.
  20. ↑ "AACR to Honor Individuals With Scientific Achievement Awards, Lectures During Annual Meeting". Targeted Oncology. Retrieved 28 April 2022.
  21. ↑ "NCI Outstanding Investigator Award Recipients". National Cancer Institute. 2015-10-14. Retrieved 2018-10-06.
  22. ↑ "Board of Directors | AACR About Us". American Association for Cancer Research (AACR). Retrieved 2020-05-02.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.